EntryPoint Capital LLC Takes Position in ClearPoint Neuro, Inc. $CLPT

Key Points

• EntryPoint Capital LLC has made a new investment in ClearPoint Neuro, Inc. by acquiring 36,082 shares worth approximately $429,000 during the first quarter.
• Analysts have varying views on the stock, with Stifel Nicolaus raising its price target to $9.00 while Wall Street Zen downgraded it to a "sell" rating; the average target is currently $19.67.
• ClearPoint Neuro reported a quarterly revenue of $9.22 million, falling short of earnings expectations, with analysts predicting it will post an EPS of -0.66 for the fiscal year.

EntryPoint Capital LLC acquired a new position in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 36,082 shares of the company's stock, valued at approximately $429,000. EntryPoint Capital LLC owned about 0.13% of ClearPoint Neuro as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Deutsche Bank AG purchased a new stake in ClearPoint Neuro during the 1st quarter worth approximately $63,000. Tower Research Capital LLC TRC purchased a new stake in ClearPoint Neuro during the 4th quarter worth approximately $93,000. Cannon Global Investment Management LLC purchased a new stake in ClearPoint Neuro during the 1st quarter worth approximately $143,000. State of Wyoming bought a new stake in shares of ClearPoint Neuro in the 4th quarter valued at approximately $145,000. Finally, Occudo Quantitative Strategies LP bought a new stake in shares of ClearPoint Neuro in the 4th quarter valued at approximately $155,000. 30.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on CLPT shares. Stifel Nicolaus raised their price objective on ClearPoint Neuro from $8.00 to $9.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Wall Street Zen cut ClearPoint Neuro from a "hold" rating to a "sell" rating in a research note on Saturday, July 12th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $19.67.

ClearPoint Neuro Stock Performance

CLPT traded down $0.1510 during trading hours on Monday, hitting $10.5490. 115,184 shares of the stock were exchanged, compared to its average volume of 317,693. The stock has a 50-day simple moving average of $11.22 and a 200-day simple moving average of $12.75. ClearPoint Neuro, Inc. has a 12 month low of $9.76 and a 12 month high of $19.22. The stock has a market cap of $299.91 million, a price-to-earnings ratio of -12.99 and a beta of 0.85. The company has a debt-to-equity ratio of 1.46, a current ratio of 7.30 and a quick ratio of 6.45.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The company had revenue of $9.22 million for the quarter, compared to the consensus estimate of $9.20 million. ClearPoint Neuro had a negative return on equity of 94.44% and a negative net margin of 66.15%. ClearPoint Neuro has set its FY 2025 guidance at EPS. Analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Timothy T. Richards sold 10,000 shares of the company's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $13.28, for a total transaction of $132,800.00. Following the completion of the transaction, the director directly owned 77,381 shares in the company, valued at $1,027,619.68. This represents a 11.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Joseph Burnett sold 21,247 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $13.29, for a total value of $282,372.63. Following the transaction, the chief executive officer owned 243,522 shares of the company's stock, valued at approximately $3,236,407.38. The trade was a 8.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.11% of the stock is owned by corporate insiders.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.